N E W S B Y T E S
Sunfox secures ₹ 15 crore in preseries funding to scale global expansion
India approves shorter treatment regimen for drug-resistant TB
The Union Ministry of Health & Family Welfare has approved the introduction of the BPaLM regimen , a new treatment for Multi-Drug- Resistant Tuberculosis ( MDR-TB ), under the National TB Elimination Program ( NTEP ). This four-drug combination of Bedaquiline , Pretomanid , Linezolid , and Moxifloxacin reduces the treatment duration to six months from the previous 20 months , offering a higher success rate with fewer side effects . With over 75,000 drug-resistant TB patients , this novel treatment is expected to accelerate India ' s goal of eliminating TB by 2025 , aligning with Prime Minister Modi ’ s vision .
This significant move , supported by a comprehensive Health Technology Assessment , ensures safety and cost-effectiveness . The Central TB Division is preparing for a nationwide rollout , which includes training health professionals . The National Strategic Plan for TB Elimination also emphasizes detecting patients , particularly in high-risk groups , and implementing Universal Drug Susceptibility Testing ( UDST ).
Sunfox Technologies has raised an additional ₹ 15 crore in pre-series funding , led by Venture Catalyst , Finvolve , Brew Opportunities Fund , and others , bringing the total raised to ₹ 20 crore . This capital will support the global expansion of Sunfox ’ s innovative Spandan , a portable ECG device that offers real-time heart health monitoring . Spandan has already been used by over 30,000 people across 20 countries , saving 10,000 lives through early detection of heart issues .
With this capital , Sunfox plans to expand both domestically and internationally . CEO Rajat Jain envisions Spandan becoming a household device , revolutionizing heart health by making early cardiac care accessible globally .
38
BioVoiceNews | October 2024